Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
| ▸ | TRPV6 | Q9H1D0 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2331568 | 0.98 | KDM4E (0.63) | KDM4EALDH1A1MEN1KMT2ARECQL | |
| SCHEMBL13943667 | 0.98 | SIGMAR1 (0.64) | KDM4EALDH1A1MEN1KMT2ARECQL | |
| SCHEMBL24163317 | 0.95 | RECQL (0.69) | KDM4EALDH1A1MEN1KMT2ARECQL | |
| SCHEMBL16225992 | 0.94 | KMT2A (0.59) | KDM4EALDH1A1MEN1KMT2ARECQL | |
| SCHEMBL4797625 | 0.91 | SIGMAR1 (0.69) | RECQLSMN1; SMN2SIGMAR1TRPV6TSHR | |
| SCHEMBL5050001 | 0.90 | L3MBTL3 (0.59) | KDM4EALDH1A1MEN1KMT2ARECQL | |
| SCHEMBL28851994 | 0.90 | KDM4E (0.55) | KDM4EALDH1A1MEN1KMT2ARECQL | |
| SCHEMBL5052507 | 0.90 | L3MBTL3 (0.59) | KDM4EALDH1A1MEN1KMT2ARECQL | |
| SCHEMBL3709310 | 0.89 | RECQL (0.70) | KDM4EALDH1A1RECQLSMN1; SMN2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL3706762 | 0.88 | RECQL (0.68) | KDM4EALDH1A1RECQLSMN1; SMN2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102197028-A | Piperidine derivative and piperazine derivative, and therapeutic agent for diseases associated with central nervous system disorders | MS SCIENCE CORP | 2011-09-21 | — | — | CN | claimed |
| EP-2357171-A1 | PIPERIDINE DERIVATIVE, PIPERAZINE DERIVATIVE AND AGENT FOR TREATMENT OF DISEASE INVOLVING CENTRAL NERVOUS SYSTEM DISORDERS | M's Science Corporation (JP) | 2011-08-17 | — | — | EP | claimed |
| CN-1107060-C | Piperazingl cyclohexanols and compositions containing same and use thereof | BRISTOL MYERS SQUIBB CO (US) | 2003-04-30 | — | — | CN | claimed |
| CN-1229796-A | Piperazingl cyclohexanols and compositions containing same and use thereof | BRISTOL MYERS SQUIBB CO (US) | 1999-09-29 | — | — | CN | claimed |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | INVITROGEN CORPORATION | 2016-10-27 | — | — | US | disclosed |
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | INVITROGEN CORPORATION | 2016-10-27 | — | — | US | disclosed |
| US-20110263862-A1 | PIPERIDINE DERIVATIVE, PIPERAZINE DERIVATIVE AND AGENT FOR TREATMENT OF DISEASE INVOLVING CENTRAL NERVOUS SYSTEM DISORDERS | M'S SCIENCE CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263862-A1 | PIPERIDINE DERIVATIVE, PIPERAZINE DERIVATIVE AND AGENT FOR TREATMENT OF DISEASE INVOLVING CENTRAL NERVOUS SYSTEM DISORDERS | M'S SCIENCE CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263862-A1 | PIPERIDINE DERIVATIVE, PIPERAZINE DERIVATIVE AND AGENT FOR TREATMENT OF DISEASE INVOLVING CENTRAL NERVOUS SYSTEM DISORDERS | M'S SCIENCE CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| CN-102197028-A | Piperidine derivative and piperazine derivative, and therapeutic agent for diseases associated with central nervous system disorders | MS SCIENCE CORP | 2011-09-21 | — | — | CN | disclosed |
| EP-2357171-A1 | PIPERIDINE DERIVATIVE, PIPERAZINE DERIVATIVE AND AGENT FOR TREATMENT OF DISEASE INVOLVING CENTRAL NERVOUS SYSTEM DISORDERS | M's Science Corporation (JP) | 2011-08-17 | — | — | EP | disclosed |
| WO-2009021944-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | KDM4E 1755/4885ALDH1A1 1121/4885MEN1 2824/4885 |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | FASN, LIPC, SREBF2 | KDM4E 1755/4885ALDH1A1 1121/4885MEN1 2824/4885 |
| US-20110263862-A1 | PIPERIDINE DERIVATIVE, PIPERAZINE DERIVATIVE AND AGENT FOR TREATMENT OF DISEASE INVOLVING CENTRAL NERVOUS SYSTEM DISORDERS | SIGMAR1, OPRL1, OPRK1 | KDM4E 4119/4885ALDH1A1 671/4885MEN1 4042/4885 |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | KDM4E 1755/4885ALDH1A1 1121/4885MEN1 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.